实体器官移植中耳念珠菌筛查的伦理优先事项
本文讨论耳念珠菌在实体器官移植中的定植对移植候选资格与移植后结局的伦理意义。美国尚无国家或专业指南规定筛查对象、方法与时机,也缺乏筛查结果如何影响患者照护的共识。作者提出基于风险的筛查作为折中方案,强调移植前筛查的根本目标是减害与个体化风险评估。
要点
- 耳念珠菌定植可能影响移植候选资格与移植后结局,需纳入伦理讨论。
- 美国尚无指南明确耳念珠菌筛查的对象、方法与时机。
- 基于风险的筛查可作为数据尚不充分时期的折中策略。
核心结论
- 移植前耳念珠菌筛查的根本目标是通过准备与个体化风险评估实现减害,而非反映机构风险容忍度或筛查政策的实施产物。
研究设计与样本
- 本文为综述/观点类文章,讨论实体器官移植中耳念珠菌筛查的伦理问题,未报告检索范围与样本量。
主要发现
- 耳念珠菌是新兴多重耐药真菌病原体,在实体器官移植中日益受到关注,定植可能影响移植前候选资格与移植后结局。
- 美国尚无国家或专业指南规定耳念珠菌筛查的对象、方法或时机,对筛查结果如何影响患者照护亦无共识。
关键数值与推荐
- 文章提出基于风险的筛查作为医院与医生制定价值导向、循证指南的折中方案,未给出具体筛查标准或数值。
临床怎么用
- 在缺乏指南的情况下,可考虑对实体器官移植受者围移植期采取基于风险的耳念珠菌筛查,并结合个体化风险评估进行决策。
局限性
- 文章为观点/综述类,未报告系统检索方法与原始数据,相关证据仍在涌现与演变中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Candida auris is an emerging, multidrug-resistant fungal pathogen of growing concern in solid organ transplantation, where colonization may have implications for pretransplant candidacy and post-transplant outcomes. Although C. auris screening is increasingly common in presurgical and critical care settings, no national or professional guidelines in the United States specify who, how, or when to screen, nor is there consensus on how screening results should impact patient care. Here, we examine the ethical significance of C. auris colonization in transplant candidacy decisions and outline the arguments for and against universal C. auris screening of solid organ recipients in the peritransplant period. We propose risk-based screening as a middle-ground approach for hospitals and physicians seeking to develop value-informed, evidence-based guidelines at a time when data are still emerging and evolving. Ultimately, the fundamental goal of pretransplant screening is harm reduction through preparedness and individualized risk assessment, not a proxy for institutional risk tolerance or an artifact of how a screening policy is applied.
引用
- Li LX, Modlin CE. Ethical Priorities for Candida auris Screening in Solid Organ Transplantation. Clin Infect Dis. 2026. PMID: 42789494. doi:10.1093/cid/ciag536
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。